1. Home
  2. Browse Decisions
  3. F.Supp.2d
  4. 264 F.Supp.2d
  5. 264 F.Supp.2d 753 (2003)
 

ELI LILLY AND CO. v. ZENITH GOLDLINE PHARM., INC.

Cause No. IP99-0038-C-H/K.

264 F.Supp.2d 753 (2003)

ELI LILLY AND COMPANY and Reliant Pharmaceuticals, LLC, Plaintiffs, v. ZENITH GOLDLINE PHARMACEUTICALS, INC., Defendant.

United States District Court, S.D. Indiana, Indianapolis Division.

May 15, 2003.

Attorney(s) appearing for the Case

Jan M. Carroll, Barnes & Thornburg, Indianapolis, IN, Ronald L. Grudziecki, R. Danny Huntington, Burns, Doane, Swecker & Mathis, Alexandria, VA, David A. Nelson, Latham & Watkins, Chicago, IL, for Plaintiffs.

Stephen E. Arthur, Harrison & Moberly, Indianapolis, IN, William L. Mentlik, Lerner, David, Littenberg, Krumholz & Mentlik, Westfield, NJ, for Defendant.

HAMILTON, District Judge.

ENTRY ON FEE PETITION

This patent case is now before the court on plaintiffs petition for an award of attorney fees and costs under 35 U.S.C. § 285. As explained below, the court awards attorney fees of $1,523,580.85 and costs of $101,576.34.

United States Patent No. 4,375,547 claimed the invention of the drug nizatidine, which plaintiff Eli Lilly and Company has marketed as Axid®. Defendant Zenith Goldline Pharmaceuticals...

Let's get started

Leagle.com

Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.

  • Updated daily.
  • Uncompromising quality.
  • Complete, Accurate, Current.

Listed below are the cases that are cited in this Featured Case. Click the citation to see the full text of the cited case. Citations are also linked in the body of the Featured Case.

Cited Cases

  • No Cases Found

Listed below are those cases in which this Featured Case is cited. Click on the case name to see the full text of the citing case.

Citing Cases